EP3184101A1 — Levodopa and carbidopa modified release composition
Assigned to Sandoz AG · Expires 2017-06-28 · 9y expired
What this patent protects
The present invention belongs to the field of pharmaceutical industry and refers to a multilayered coated particle that comprises levodopa, carbidopa in the form of carbidopa monohydrate and carboxylic acid (tartaric acid). The present invention further refers to a pharmaceutical…
USPTO Abstract
The present invention belongs to the field of pharmaceutical industry and refers to a multilayered coated particle that comprises levodopa, carbidopa in the form of carbidopa monohydrate and carboxylic acid (tartaric acid). The present invention further refers to a pharmaceutical composition and a dosage form comprising one or more of said multilayered coated particle(s). Moreover, the present invention refers to a process for preparing said particle, pharmaceutical composition and dosage form, and to the use of said dosage form in the treatment of Parkinson's disease.
Drugs covered by this patent
- Sinemet Cr (CARBIDOPA) · Aton
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.